KOSPIBiotech & Pharma003000

Bukwang Pharmaceutical Ind

₩3,800▼ 1.81%2026-11-18 close
Market Cap
₩374.9B
Turnover
₩600M
Volume
160K
Shares out.
98.7M
PER
50.1×
PBR
1.1×
EPS
₩77
Dividend Yield
3.24%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩125 per share · Prices as of the 2026-11-18 close

01

Report overview

Bukwang Pharmaceutical: Profitable Core, Heavier R&D Load

Bukwang Pharmaceutical has stayed profitable at the operating line since 2025, but the self-funded Phase 2 trial of its Parkinson's candidate CP-012 is weighing on the pace of earnings recovery.

  1. 1

    Revenue reached KRW 200.7 billion and operating profit KRW 14.2 billion in 2025, the largest year in the 2022–2025 period, with operating profit up 775.6% from KRW 1.62 billion in 2024.

  2. 2

    After a KRW 1.1 billion operating profit trough in Q1 2026, operating profit rose to KRW 1.41 billion in Q2 and KRW 1.73 billion in Q3, yet Q3 profit attributable to controlling shareholders fell 81.1% year on year to KRW 290 million.

  3. 3

    Cumulative R&D expense through Q3 2026 rose 29.5% to KRW 16.9 billion as the CP-012 global Phase 2 trial ramped up, and the company puts the trial at roughly two years and KRW 20 billion in total cost.

  4. 4

    On April 27, 2026, the company acquired 60 million shares for a 74.97% stake in a Korean manufacturing affiliate, with production capacity expansion as the stated aim.

  5. 5

    An R&D Day on November 24, 2026 is scheduled to launch the new RNA subsidiary and disclose its platform technology and new pipeline.

02

Business structure

Bukwang Pharmaceutical runs a prescription-drug finished-medicines business alongside early-stage drug research. Its core franchises are central nervous system (CNS) drugs and diabetic neuropathy treatments, with Latuda as a flagship product.

In early 2026 it launched a sustained-release insomnia treatment and an epilepsy drug. According to a Bio Times report, the diabetic neuropathy franchise grew about 43% in 2025 and the CNS strategic portfolio rose about 91%.

The company said prescription volume for its prescription drugs grew 8.7% year on year in Q1 2026 based on Yuhan data, with the CNS unit up 36%. Subsidiaries include Bukwang Medica, a Danish R&D unit Contera Pharma, Dyna Therapeutics, and Israel-based ProteKt Therapeutics.

As of a September 2025 report, all but Bukwang Medica were R&D entities with no revenue. Bukwang Medica is the subsidiary that has driven group sales growth.

On the production side, the company is automating its Ansan plant and has shifted some OTC and toothpaste production to outside manufacturers, a shift that weighed on Q1 2026 profit. Distribution volumes move quarter to quarter with wholesaler inventory levels.

The company also has a five-product co-promotion arrangement with Servier Korea. An industry analysis puts the Korean schizophrenia drug market at KRW 200 billion to KRW 240 billion.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩47.8B₩1B2.0%
2025Q4₩62.5B₩8.2B13.0%
2026Q1₩47.8B₩1.1B2.3%
2026Q2₩57B₩1.4B2.5%
2026Q3₩56.1B₩1.7B3.1%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩190.9B-₩200M-₩2.5B−0.1%−0.9%47.5%
2023₩125.9B-₩37.5B-₩31.3B−29.8%−13.8%83.1%
2024₩160.1B₩1.6B-₩2.6B1.0%−1.1%52.9%
2025₩200.7B₩14.2B₩12.6B7.1%3.7%39.7%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

Annual revenue went from KRW 190.9 billion in 2022 to KRW 125.9 billion in 2023, a 34.0% decline, then rose 27.1% to KRW 160.1 billion in 2024 and 25.4% to KRW 200.7 billion in 2025, two consecutive years of growth.

Operating loss was KRW 231 million in 2022 and widened to KRW 37.5 billion in 2023, before turning to an operating profit of KRW 1.62 billion in 2024. Operating profit reached KRW 14.2 billion in 2025, up 775.6%, with an operating margin of 7.1%, after margins of -29.8% in 2023 and 1.0% in 2024.

Profit attributable to controlling shareholders swung from a loss of KRW 2.64 billion in 2024 to a profit of KRW 12.6 billion in 2025, and net profit including non-controlling interests was KRW 12.4 billion.

A press report says the ratio of ordinary R&D expense to revenue fell from 27.4% in 2023 to 14.6% in 2024 and 9.7% in 2025. Operating cash flow was KRW 16.5 billion in 2022, -KRW 9.36 billion in 2023, KRW 34.4 billion in 2024, and KRW 21.5 billion in 2025.

On a quarterly basis, Q3 2025 revenue of KRW 47.8 billion and operating profit of KRW 979 million were followed by Q4 2025 revenue of KRW 62.5 billion (up 30.7% quarter on quarter) and operating profit of KRW 8.16 billion (up 733.2%).

Q1 2026 revenue was KRW 47.8 billion (down 23.6% quarter on quarter) and operating profit KRW 1.1 billion (down 86.5%), the low point in the series. The company attributed the drop to higher production costs from expanded outsourced manufacturing to prevent shortages.

Q2 2026 revenue was KRW 57 billion with operating profit of KRW 1.41 billion, and Q3 2026 revenue was KRW 56.1 billion with operating profit of KRW 1.73 billion, so operating profit rose for two straight quarters.

Profit attributable to controlling shareholders, however, fell to KRW 290 million in Q3 2026, down 81.1% year on year. Over the last four quarters, from Q4 2025 through Q3 2026, that profit totaled KRW 7.54 billion.

05

Industry analysis

For Bukwang Pharmaceutical, earnings in the Korean prescription drug market depend heavily on prescription growth and on wholesaler inventory adjustments.

The company said that in Q1 2026 the end of a medical-service disruption led wholesalers to cut stock, which reduced prescription-drug demand relative to the prior-year quarter. Even so, prescription volume grew 8.7% year on year that quarter, well above the market growth rate of about 1%, according to company data.

On costs, a press report noted that a stronger won raised the cost of imported raw materials and finished products. A 2025 analysis shows R&D spending as a share of revenue rising from 9.88% in 2015 to 13.41% in 2020 and 17.73% in 2024.

In Parkinson's disease, CP-012 is in a global Phase 2 trial, and any commercial path depends on trial results. The company continues its RNA therapeutics research collaboration with Lundbeck, and it is evaluating a preclinical licensing deal for the rare-disease asset CP-102.

Revenue went from KRW 141.7 billion in 2015 to KRW 194.2 billion in 2018 before declining, and the KRW 200.7 billion recorded in 2025 is above that earlier peak. Competitively, the company is widening its CNS prescription share through new launches and co-promotion with Servier.

06

Outlook

The company expects revenue and operating profit to recover to the levels of its historical trend and its target after Q2 2026. New product launches and a cardiovascular product launched with Servier were cited as growth drivers.

Launches of a calcium and vitamin D combination and an antihypertensive are also scheduled. With the Korean manufacturing affiliate, the company plans joint sales of about 27 products and aims to move some OTC production there to free capacity for prescription drugs.

Management expects that affiliate's utilization rate to rise meaningfully by year-end 2026. In its Q3 2026 remarks, the company said it plans to expand new prescriptions in cardiovascular and respiratory drugs in Q4 and to push coding activity for new products in hospitals.

Latuda has received approval for a domestic Phase 3 trial protocol to add an adjunctive indication for major depressive disorder, and the company targets KRW 30 billion in annual sales within three years.

On the pipeline side, CP-012 is set to begin first patient visits and dosing in the United States in November 2026, with first patient visits in Europe expected in Q1 2027. Topline results are projected for early 2028.

The new RNA subsidiary launches in November 2026, and the company plans to present its platform technology, new pipeline, and medium-term strategy at an R&D Day on November 24.

07

Valuation

PER
50.1×
PBR
1.1×
ROE
2.2%
EPS
₩77
BPS
₩3,364
Dividend per share
₩125

Bukwang Pharmaceutical's earnings multiple sits at a high level relative to its recent profit base.

Profit attributable to controlling shareholders totaled KRW 7.54 billion over the last four quarters, from Q4 2025 through Q3 2026, compared with KRW 12.6 billion for full-year 2025, so the earnings base has narrowed in 2026.

Because the company only returned to profit in 2024 and 2025, a long history of earnings-based multiples is not yet available. The price-to-book ratio reflects a modest premium to net assets.

At year-end 2025, total equity was KRW 340.9 billion, of which KRW 340.6 billion belonged to controlling shareholders, and total liabilities were KRW 135.4 billion. Operating cash flow was KRW 21.5 billion in 2025, down from KRW 34.4 billion in 2024.

Multiples move with both price and earnings, so a recovery in profit would lower the multiple at a given share price. Conversely, while R&D spending is holding down profit, the multiple can stay elevated.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Revenue growth and a shift to profitability

Revenue rose in both 2024 and 2025, reaching KRW 200.7 billion in 2025, the largest year in the period. The operating margin improved from -29.8% in 2023 to 7.1% in 2025, and every quarter from Q3 2025 through Q3 2026 posted an operating profit.

CNS franchise and new product expansion

The company says its CNS strategic portfolio grew about 91% in 2025 and CNS prescriptions rose 36% in Q1 2026. Alongside two recent launches, a five-product co-promotion with Servier is cited as a route to more prescriptions. The target of KRW 30 billion in annual Latuda sales within three years is another pillar of the growth plan.

Production capacity and cost structure plans

With a 74.97% stake in a Korean manufacturing affiliate secured on April 27, 2026, the company has a base for expanding production capacity. Management says outsourced-production costs should ease once the production portfolio is reorganized after the acquisition. It presents the back-to-back operating profit gains in Q2 and Q3 2026 as early evidence of that plan.

09

Bear factors

Quarterly earnings volatility and weaker controlling-shareholder profit

Operating profit fell 86.5% quarter on quarter to KRW 1.1 billion in Q1 2026. Profit attributable to controlling shareholders fell 81.1% year on year to KRW 290 million in Q3 2026. Over the last four quarters that profit totaled only KRW 7.54 billion, a thin base. Wholesaler stock adjustments also keep quarterly revenue volatile.

R&D burden and trial costs

The CP-012 Phase 2 trial is described as roughly two years and KRW 20 billion in total cost. Cumulative R&D expense through Q3 2026 rose 29.5% to KRW 16.9 billion. The company posted an operating loss of KRW 37.5 billion in 2023, which analysts attribute largely to drug development costs at its subsidiaries. A renewed rise in R&D could put the profit trend at risk.

Cost pressure, currency and execution risk in production shift

The main driver of the Q1 2026 profit drop was higher manufacturing costs from expanded outsourced production. A press report also cited a weaker won raising the cost of imported materials and finished products.

If normalization of the newly acquired plant and external CMO orders slip, the expected cost relief could be delayed.

10

Risk factors

Clinical outcome risk

CP-012 is in a global Phase 2 trial for morning akinesia in Parkinson's disease, with topline data projected for early 2028. If results fall short, the path to recovering the R&D invested narrows.

The company has also flagged a potential licensing deal for CP-102, a rare-disease asset whose commercial case will depend on its own data.

Acquisition and production integration risk

The acquired manufacturer went through a court-supervised restructuring, and disclosures note that timing may shift with the restructuring plan and court approvals. The company plans to move some OTC production there and expand CMO orders, but slower execution would delay the utilization gains. Integration costs could weigh on near-term profit.

Earnings volatility and cash flow risk

Operating cash flow was -KRW 9.36 billion in 2023 and KRW 21.5 billion in 2025, down from KRW 34.4 billion in 2024. The company raised about KRW 89.3 billion through a 2025 rights offering, but that capital is tied to plant investment and R&D plans. Quarterly revenue and profit continue to swing with wholesaler stock and prescription flow.

11

What to watch next

  1. November 24, 2026

    The R&D Day is scheduled to launch the new RNA subsidiary and disclose platform technology, new pipeline assets, and medium-term strategy. It is the venue to check the concrete timing and resource allocation of the pipeline.

  2. November 2026

    First patient visits and dosing in the U.S. for the CP-012 trial are planned for this month. Whether dosing starts on schedule will show whether the Phase 2 timeline is on track.

  3. Q1 2027

    First patient visits in Europe are expected in Q1 2027. The enrollment pace in the U.S. and Europe bears directly on how fast trial spending runs.

  4. Around late March 2027

    The 2026 annual business report is due. It will fix full-year 2026 revenue, operating profit, Q4 results, and the level of R&D spending in DART filings.

  5. Early 2028

    Topline data from the CP-012 Phase 2 trial are projected for early 2028. The result will shape the follow-on development path and the licensing outlook.

12

Overall view

Bukwang Pharmaceutical posted its largest year in the reported period in 2025, with revenue of KRW 200.7 billion and operating profit of KRW 14.2 billion, lifting the operating margin to 7.1% from a loss-making 2023.

Operating profit stayed positive in every quarter through Q3 2026, and it rose in Q2 and Q3 after a Q1 trough. Profit attributable to controlling shareholders, however, fell 81.1% year on year to KRW 290 million in Q3 2026.

The self-funded Phase 2 trial for CP-012 is described as about KRW 20 billion over roughly two years, so R&D spending will keep constraining profit for now.

Securing a 74.97% stake in the Korean manufacturing affiliate could change the company's production capacity and cost structure, but the effect depends on execution. This report offers no investment rating, recommendation, or target price.

The next checkpoints are the November 24, 2026 R&D Day, the first U.S. dosing for CP-012, and the 2026 annual business report due around late March 2027.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. digitaltoday.co.kr
  2. thelec.kr
  3. fnnews.com
  4. dailypharm.com
  5. news.nate.com
  6. bosa.co.kr
  7. medicaldaily.co.kr
  8. m.news.nate.com
  9. thebionews.net
  10. widedaily.com
  11. biotimes.co.kr
  12. thebionews.net
  13. thebionews.net
  14. pharm.edaily.co.kr
  15. jobkorea.co.kr
  16. view.asiae.co.kr
  17. thebionews.net
  18. comp.wisereport.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis